The Irish Cancer Society highlights failures in Ireland’s two-tier health system, which disadvantages public cancer patients. Experts, including Dr. Michael McCarthy, reveal that 30-40% of new EMA-approved cancer drugs are unavailable to public patients, who face an average two-year wait…